Dr. Gaurav Aggarwal serves as Managing Director at Vivo Capital. He also is an Angel Investor. Aggarwal comes to Vivo with prior experience investing in private and public biopharmaceutical and medical device companies across the spectrum of development. He previously served as Managing Director with Investor Growth Capital, Partner with Panorama Capital and Associate at JPMorgan Partners. He serves as Board Member at Sierra Oncology. He was an investor and previously served on the boards of Auspex Pharmaceuticals (acquired by Teva), Hyperion Therapeutics (acquired by Horizon), NextWave Pharmaceuticals (acquired by Pfizer), Piramed (acquired by Roche) and Flowcardia (acquired by CR Bard). Other successful investments include Amarin, ISTA Pharmaceuticals and Spinal Concepts. In addition to his role as an investor, Aggarwal was the Chief Business Officer of Ocera Therapeutics, a publicly traded clinical stage company developing therapies for orphan liver conditions. Aggarwal received his M.D. from Columbia University, College of Physicians & Surgeons, and his B.S. in Agricultural Economics from Cornell University.